Literature DB >> 32653677

EQUIDopa: A responsive web application for the levodopa equivalent dose calculator.

Domen Verber1, Damijan Novak2, Mladen Borovič2, Jani Dugonik2, Dušan Flisar3.   

Abstract

BACKGROUND AND
OBJECTIVE: Levodopa/carbidopa intestinal gel infusion is a treatment option for patients of advanced stage of Parkinson's disease. This treatment requires the time-consuming and error-prone conversion of orally taken antiparkinson drugs into an equivalent replacing dose of levodopa/carbidopa, which is delivered via pump. In order to facilitate and speed up this conversion process, we developed a specific user-friendly application that would be available online or as a standalone mobile application. Such an application has now been written and designed in collaboration with a computer scientist and physician, who is also intended to be the final user.
METHODS: The levodopa equivalent dose calculations are based on previous studies and data reported in the literature. Two related on-line conversion applications were analyzed and evaluated. The primary objectives of the application were determined, and basic functionalities were outlined. The application was implemented using modern development tools and frameworks.
RESULTS: The application has proven to be effective and easy to use in our clinical setting. It can serve as a control for manual calculations made by medical staff. It can also be applied as a useful tool in levodopa/carbidopa intestinal gel infusion courses for the advanced treatment of Parkinson's disease.
CONCLUSION: The presented application could replace the tedious and error-prone levodopa equivalent dose conversion of antiparkinson drugs efficiently. In comparison to related on-line conversion applications, this specific application provides more functionality, reduces the risk of user errors, and can be run on a variety of devices. The conversion value provided by the application is only an estimate. The effect of the drugs is specific for each individual patient, which could not be considered in the calculations. Therefore, the responsibility of using the results of the application rests with the clinical judgment of the user. Nevertheless, the application can give us a good starting point for the initial pump setting, which would be adjusted further during the titration period, according to the patient's response.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Angular; Duodopa(Ⓡ); Levodopa; Levodopa equivalent dose calculator; Parkinson's disease; Responsive web application

Mesh:

Substances:

Year:  2020        PMID: 32653677     DOI: 10.1016/j.cmpb.2020.105633

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  5 in total

1.  Myeloperoxidase and Advanced Oxidation Protein Products in the Cerebrospinal Fluid in Women and Men with Parkinson's Disease.

Authors:  Emilio Fernández-Espejo; Fernando Rodríguez de Fonseca; Ana Luisa Gavito; Antonio Córdoba-Fernández; José Chacón; Ángel Martín de Pablos
Journal:  Antioxidants (Basel)       Date:  2022-05-30

2.  Personality Changes After Subthalamic Nucleus Stimulation in Parkinson's Disease.

Authors:  Simon Brezovar; Lucija Pažek; Martin Kavčič; Dejan Georgiev; Maja Trošt; Dušan Flisar
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

3.  Salivary ATP13A2 is a potential marker of therapy-induced motor complications and is expressed by inclusions in submandibulary glands in Parkinson ´s disease.

Authors:  Emilio Fernández-Espejo; Ana L Gavito; Juan Suárez; Eduardo Tolosa; Dolores Vilas; Iban Aldecoa; Joan Berenguer; Antonio Córdoba-Fernández; Fátima Damas-Hermoso; Fernando Rodríguez de Fonseca
Journal:  Clin Park Relat Disord       Date:  2022-08-28

4.  Effectiveness of Acupuncture for Anxiety Among Patients With Parkinson Disease: A Randomized Clinical Trial.

Authors:  Jing-Qi Fan; Wei-Jing Lu; Wei-Qiang Tan; Xin Liu; Yu-Ting Wang; Nan-Bu Wang; Li-Xing Zhuang
Journal:  JAMA Netw Open       Date:  2022-09-01

5.  Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson's Disease.

Authors:  Emilio Fernández-Espejo; Fernando Rodríguez de Fonseca; Juan Suárez; Eduardo Tolosa; Dolores Vilas; Iban Aldecoa; Joan Berenguer; Fátima Damas-Hermoso
Journal:  Antioxidants (Basel)       Date:  2021-05-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.